Additional USFDA Indication and U. S. Patent for Veritas® Collagen Matrix, Granted to Synovis
Filed in archive Diagnostics , Treatment by Gloria Gamat on January 14, 2007

Veritas® minimizes internal tissue attachment, a common and painful post-surgical complication.
Veritas is a biological material derived from bovine pericardium (a sac-shaped tissue surrounding the heart), which exhibits great suppleness and durability. As it is being placed in the human body, it handles and conforms like the patient's own tissue facilitating the surgical procedure and enabling normal healing.
The USFDA has granted the additional indication following Synovis' completion of a research in 2006 that investigated the adhesion formation and the tenacity of adhesions post surgery, and demonstrated that Veritas implants had minimal tissue attachment.
In addition to Synovis' U.S. patent for the process to manufacture Veritas, the company has just been issued another U.S. patent for "a method and composition for preventing surgical adhesions."
According to Richard Kramp, president and chief executive officer of Synovis Life Technologies:
"Receiving this additional indication from the FDA for Veritas is significant news for Synovis, and supports our strategy to maximize the applications for Veritas in many areas of soft tissuerepair."
Find more details from the press release.
Permalink: Additional USFDA Indication and U. S. Patent for Veritas® Collagen Matrix, Granted to Synovis
Tags:
surgical implant Veritas Collagen Matrix synovis collagen+matrix veritasâ+collagen
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/49344









